2006
DOI: 10.1016/j.cgh.2006.06.004
|View full text |Cite
|
Sign up to set email alerts
|

Cholecystitis After Metallic Stent Placement in Patients With Malignant Distal Biliary Obstruction

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

7
111
3
5

Year Published

2008
2008
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 156 publications
(126 citation statements)
references
References 28 publications
7
111
3
5
Order By: Relevance
“…Tumor involvement at the orifice of the CD, as in our case, is a risk factor for cholecystitis [2,3] . In patients in whom the cholecystitis does not resolve with conservative therapy, percutaneous cholecystostomy may be necessary [3] . In our patient, however, there was no window for percutaneous transhepatic drainage.…”
Section: Discussionsupporting
confidence: 51%
See 1 more Smart Citation
“…Tumor involvement at the orifice of the CD, as in our case, is a risk factor for cholecystitis [2,3] . In patients in whom the cholecystitis does not resolve with conservative therapy, percutaneous cholecystostomy may be necessary [3] . In our patient, however, there was no window for percutaneous transhepatic drainage.…”
Section: Discussionsupporting
confidence: 51%
“…There is, however, a need to prevent and manage stent-related complications. Acute cholecystitis after SEMS placement is a serious complication, and tumor involvement at the orifice of the cystic duct (CD) is a risk factor [2,3] . Some patients with cholecystitis improve with conservative therapy, while others require percutaneous drainage.…”
Section: Introductionmentioning
confidence: 99%
“…210 However multiple studies have shown that the primary risk for developing cholecystitis after ERCP is tumor involvement of the cystic duct orifice, regardless of whether a covered or uncovered metal stent is used. [211][212][213] Thus, whether cholecystitis occurs as a result of the stent itself versus the actual tumor biology is unclear. As the literature is not definitive it is not unreasonable for endoscopists to assess the location of the cystic duct orifice during ERCP to choose the appropriate length and size stent whose proximal end will terminate distal to the cystic take off.…”
Section: Risk Reductionmentioning
confidence: 99%
“…Die Behandlung sollte anhand nichtinvasiver Bildgebung -am besten der MRCP -geplant und individuell durchge- [9,15,16]. FĂŒr den Wallstent fand sich kein signifikanter Unterschied in der Offenheitsrate [17], aber eine relativ hohe Komplikationsrate von 23,2% [18] und in einer prospektiven Studie eine hohe Cholezystitis-HĂ€ufigkeit von 10% [29].…”
Section: Cholangiocarcinoma: Update Of New Stents For Palliationunclassified